FDA Approves Nivolumab for the Treatment of Metastatic Squamous Non-small Cell Lung Cancer

FDA Approves Nivolumab for the Treatment of Metastatic Squamous Non-small Cell Lung Cancer

shutterstock_173790782The U.S. Food and Drug Administration recently approved the medication nivolumab (Opdivo; Bristol-Myers Squibb Company) as a therapy for patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after chemotherapy treatment.

NSCLC is the most common type of lung cancer, accounting for around 85% of all lung cancers. NSCLCs are known to be relatively insensitive to chemotherapy.

Nivolumab corresponds to a monoclonal antibody that recognizes and binds to the programmed death 1 (PD-1) receptor, which is thought to be involved in suppressing the immune system in particular situations, such as pregnancy or autoimmune diseases. By blocking the PD-1 cellular pathway, the immune response in no longer inhibited and consequently, anti-tumor immune responses can be developed. Nivolumab has been approved in December 2014 for the treatment of unresectable or metastatic melanoma.

The FDA approval was based on results from a randomized, open-label clinical trial in 272 patients with metastatic squamous NSCLC, who have had disease progression during or after one prior platinum-based chemotherapy regimen (generally used against advanced, metastatic forms of cancer). Patients received either nivolumab (n=135) at 3 mg/kg intravenously every 2 weeks, or docetaxel (n=137; an effective chemotherapeutic drug) 75 mg/m2 intravenously every 3 weeks. Researchers found that patients under nivolumab or docetaxel had superior overall survival (OS), with a higher median OS of 9.2 months for patients under nivolumab treatment in comparison to a median OS of 6 months for patients under docetaxel.

[adrotate group=”3″]

These results were supported by an additional trial also based in patients with metastatic squamous NSCLC and disease progression after receiving a platinum-based therapy. 117 patients received nivolumab, at 3 mg/kg intravenously every 2 weeks, and the main efficacy outcome measure was confirmed objective response rate (ORR). An ORR of 15% was obtained in this trial, which means 15% of the patients had a reduction in cancer burden.

The most common adverse reactions reported in patients under nivolumab treatment were musculoskeletal pain, fatigue, decreased appetite, dyspnea and cough. In terms of immune-mediated adverse reactions, colitis, nephritis/renal dysfunction, hepatitis, pneumonitis, hyperthyroidism and hypothyroidism were reported.

Nivolumab was approved by the FDA as an intravenous infusion at a dose of 3mg/kg administered over 60 minutes every 2 weeks.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published.